Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Overview of genes linked to early and late onset myasthenia gravis

Myasthenia gravis is a debilitating autoimmune disorder that manifests clinically as muscle weakness and fatigability. Early and late onset forms of myasthenia gravis have distinct epidemiological and pathological characteristics. However, little is known about the immunological mechanisms that lead to the development of autoantibodies against the acetylcholine receptor in the majority of these patients.

In a new study led by Dr Lahiru Handunnetthi (Academic Clinical Lecturer at NDCN), a team of researchers used cutting-edge genomic methodology to identify disease-relevant genes. The methodology integrated genome-wide study findings with cell-type-specific information such as gene expression patterns and promotor-enhancer interactions. This approach shed light on the underlying mechanisms for early and late forms of myasthenia gravis.

The genes prioritised in this study highlight several key differences in the immunological pathways between early and late onset myasthenia gravis. The researchers identified a unique role for the innate immune system in early onset disease, whereas they found multiple layers of evidence for T-cell pathways in late onset disease. Furthermore, the researchers demonstrated for the first time that causal genetic variants linked to late onset disease result in low expression of CTLA4 in CD4+ T-cells.

The disease-relevant genes identified in this study are a unique resource for clinicians, scientists and the pharmaceutical industry. The distinct immunological pathways linked to early and late onset myasthenia gravis carry important implications for repurposing existing drugs, and for future drug development.

The researchers plan to carry out further studies at single cell level with the help of funding from the Human Immune Discovery Initiative. They are also working towards early preclinical studies to help target existing and novel therapeutic agents for early and late forms of myasthenia gravis. 

This work was carried out in collaboration with Professor Julian Knight at the Wellcome Centre for Human Genetics and Professor Sarosh Irani from NDCN as well as others from the Wellcome Sanger Institute and Estonian Genome Centre.

Read the full paper in Annals of Neurology

Similar stories

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Inside the Wade-Martins Lab for World Alzheimer’s Day 2022

This week DPAG marked World Alzheimer's Day, which took place on Wednesday 21 September 2022, with an inside look into the Wade-Martins Laboratory.

Engagement with arts and culture can have a positive impact on mental health in young people

A new study finds that engaging with arts and culture online can improve mental health in young people.

Novel Use of Ultrasound-Guided Fine Needle Aspiration of Lymph Nodes Helps Scientists Study Brain and Immunity

A new study investigates immune mechanisms that underlie a brain disease called NMDAR-antibody encephalitis, an autoimmune disease in which antibodies are produced, and subsequently disrupt brain NMDA receptors, crucial in maintaining normal brain function.